The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1479
Addendum: PCV13 for Adults 65 Years and Older
Download PDF:    US English
 Select a term to see related articles  PCV13   Pneumococcal vaccine   Pneumovax23   PPSV23   Prevnar13   vaccines 

In 2014, the US Advisory Committee on Immunization Practices (ACIP) recommended that all adults 65 years old and older being vaccinated against pneumococcus for the first time receive the pneumococcal conjugate vaccine (PCV13) followed 6 to 12 months later by the pneumococcal polysaccharide vaccine (PPSV23) (Med Lett Drugs Ther 2014; 56:102). In June 2015, the ACIP changed the recommended interval between the two vaccines to >1 year for immunocompetent adults ≥65 years old (MMWR Morbid Mortal Wkly Rep 2015; 674:944). Separating the vaccines by a year or more may improve the immune response to the serotypes in both vaccines. If a dose of PPSV23 is given earlier than the recommended interval, it does not need to be repeated.

© The Medical Letter, Inc. All Rights Reserved.
This article has been freely provided.